A single-center, open-label, randomized study of the pharmacokinetics of Azasite [azithromycin] ophthalmic solution versus Vigamox [moxifloxacin] in the tears of healthy volunteers following a single ocular administration.

Trial Profile

A single-center, open-label, randomized study of the pharmacokinetics of Azasite [azithromycin] ophthalmic solution versus Vigamox [moxifloxacin] in the tears of healthy volunteers following a single ocular administration.

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Sep 2011

At a glance

  • Drugs Azithromycin; Moxifloxacin
  • Indications Bacterial infections
  • Focus Pharmacokinetics
  • Sponsors Inspire Pharmaceuticals
  • Most Recent Events

    • 08 Dec 2009 Additional lead trial centre and Merck as company identified as reported by ClinicalTrials.gov.
    • 18 Sep 2009 Planned number of patients changed from 36 to 37 as reported by ClinicalTrials.gov.
    • 13 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top